Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Affimed N.V. (AFMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 271,397
  • Shares Outstanding, K 62,390
  • Annual Sales, $ 2,270 K
  • Annual Income, $ -34,160 K
  • 36-Month Beta 3.53
  • Price/Sales 116.76
  • Price/Cash Flow N/A
  • Price/Book 4.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.17
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.21
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +19.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.55 +180.65%
on 08/27/18
7.35 -40.82%
on 08/29/18
+2.75 (+171.88%)
since 08/17/18
3-Month
1.40 +210.71%
on 08/14/18
7.35 -40.82%
on 08/29/18
+2.32 (+114.81%)
since 06/18/18
52-Week
1.15 +278.26%
on 12/21/17
7.35 -40.82%
on 08/29/18
+2.20 (+102.33%)
since 09/18/17

Most Recent Stories

More News
Immuno Oncology & Targeted Therapy Companies Set to Breakout

HENDERSON, NV / ACCESSWIRE / September 12, 2018 / Immuno Oncology has been getting investors revved up in 2018. Abpro and Neon announced IPOs and recently, German biotech Affimed agreed to an alliance...

AFMD : 4.35 (+2.35%)
CELG : 87.61 (+0.47%)
IOVA : 13.70 (+4.58%)
Affimed (AFMD) Surges on Collaboration Contract with Roche (revised)

Affimed (AFMD) inks a strategic collaboration deal with Roche to develop a host of immunotherapies for treating different types of cancer.

AFMD : 4.35 (+2.35%)
ILMN : 350.88 (+1.05%)
GILD : 73.67 (+1.22%)
RHHBY : 30.6700 (-0.03%)
Affimed (AFMD) Soars: Stock Adds 10.8% in Session

Affimed (AFMD) was a big mover last session, as the company saw its shares rise more than 10% on the day amid huge volumes.

AFMD : 4.35 (+2.35%)
BSTC : 58.23 (-1.09%)
Affimed (AFMD) Surges On Collaboration Contract With Roche

Affimed (AFMD) inks a strategic collaboration deal with Roche to develop a host of immunotherapies for treating different types of cancer.

AFMD : 4.35 (+2.35%)
ILMN : 350.88 (+1.05%)
GILD : 73.67 (+1.22%)
RHHBY : 30.6700 (-0.03%)
Affimed Shares Leap on News of Genentech Deal, Analysts Review and Target

NEW YORK, NY / ACCESSWIRE / August 29, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

AFMD : 4.35 (+2.35%)
Biotech Stocks Take Aim At New Highs In August 2018

CORAL GABLES, FL / ACCESSWIRE / August 28, 2018 / August has been full of excitement within the biotech sector of the market. All ETF's tracking related stocks have been heading higher this month. Yesterday,...

AFMD : 4.35 (+2.35%)
ABBV : 92.61 (-2.89%)
Affirmed Therapeutics (AFMD) Reports Q2 Loss, Misses Revenue Estimates

Affirmed Therapeutics (AFMD) delivered earnings and revenue surprises of 5.88% and -70.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

AFMD : 4.35 (+2.35%)
Affimed N.V. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Affimed N.V. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30 AM Eastern Time.

AFMD : 4.35 (+2.35%)
Implied Volatility Surging for Affimed (AFMD) Stock Options

Affimed (AFMD) needs investors to pay close attention to the stock based on moves in the options market lately.

AFMD : 4.35 (+2.35%)
Today's Free Research Reports Coverage on Agenus and Three More Biotech Stocks

Stock Research Monitor: AFMD, AKCA, and AKBA

AFMD : 4.35 (+2.35%)
AKCA : 26.50 (+6.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade AFMD with:

Business Summary

Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company's TandAbs has the ability to bring NK-cells or T-cells into proximity and...

See More

Key Turning Points

2nd Resistance Point 4.58
1st Resistance Point 4.47
Last Price 4.35
1st Support Level 4.22
2nd Support Level 4.08

See More

52-Week High 7.35
Fibonacci 61.8% 4.98
Last Price 4.35
Fibonacci 50% 4.25
Fibonacci 38.2% 3.52
52-Week Low 1.15

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar